Rodman & Renshaw Assumes Can-Fite BioPharma (CANF) at Buy

August 29, 2016 7:14 AM EDT
Get Alerts CANF Hot Sheet
Price: $2.07 -8%

Rating Summary:
    2 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 23 | Down: 34 | New: 34
Trade CANF Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Rodman & Renshaw assumed coverage on Can-Fite BioPharma (NYSE: CANF) with a Buy rating and a price target of $6. Analyst Raghuram Selvaraju said the company is "underrated."

"In our view, Can-Fite constitutes an undervalued proposition within the biopharmaceutical sector, given: (1) the near-term initiation of two Phase 3 programs with validated clinical protocols for its lead candidate, piclidenoson (CF101), in rheumatoid arthritis (RA) and psoriasis, disease areas in which the drug’s activity has already been clinically demonstrated; (2) potential for its technology platform to be leveraged into various other disease areas, including cancer, NASH, and sexual dysfunction; (3) the safety advantages of the company’s proprietary molecules based on A3AR expression patterns; and (4) experienced leadership, particularly Dr. Pnina Fishman, the company’s scientific founder, who are committed to driving the company’s programs forward and attaining value-driving inflection points," said Selvaraju.

For an analyst ratings summary and ratings history on Can-Fite BioPharma click here. For more ratings news on Can-Fite BioPharma click here.

Shares of Can-Fite BioPharma closed at $2.40 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Hot New Coverage, New Coverage

Related Entities

Rodman & Renshaw

Add Your Comment